What is Insulin Lispro?

A rapid-acting mealtime insulin analog; brands include Humalog, Admelog and Lyumjev.

Insulin Lispro in the library · · Human Trials · What are peptides?

314 registered trials · 420 indexed papers · 464 human / 0 animal studies

From the PeptideWhiz library entry. "As described" sections summarize claims made in the sources; they are not PeptideWhiz endorsements.

What it is

A rapid-acting mealtime insulin analog; brands include Humalog, Admelog and Lyumjev.

Type: Rapid-acting insulin analog.

Definition (National Library of Medicine)

“Insulin that has been modified so that the B-chain contains a lysine at position 28 instead of a proline and a proline at position 29 instead of a lysine. It is used to manage blood glucose levels in patients with type 2 diabetes.”

  • MeSH: Insulin Lispro

Human research

The registered human trials and peer-reviewed human studies linked below are listed from ClinicalTrials.gov and PubMed. A study is linked only when Insulin Lispro is one of its interventions, or is named in the study title or subject headings.

Listing a study does not mean it showed a benefit, and it is not medical advice.

Registered human trials (314)

TrialPhaseStatusYearEnrolled
A Single Bolus, 12-hour Euglycemic Clamp Study of the Safety, Pharmacokinetics (PK) and Glucodynamics (GD) of Intraperitoneal (IP) Portal Insulin U-500Phase 1recruiting202625
Premixed Glucagon/Insulin Solution for Faster Insulin Absorption in Type 1 DiabetesPhase 1/Phase 2terminated20259
A Study of LY4057996 in Healthy Participants and Participants With Type 1 and Type 2 DiabetesPhase 1recruiting2025124
Testing a Conversion Factor for a More Rapidly Acting Insulin in an Automated Insulin Delivery System Among Adolescents With T1Dcompleted202511
Subcutaneous Pharmacokinetic Evaluation of Monomeric Insulin and Lyumjev in Adults With Type 1 DiabetesPhase 1completed202510
Single vs Multi-Dose Insulin for Glycemic Control (SUGAR)recruiting2025176
Do Antipsychotics Block Insulin Action in the Brain: is it a Class Effect?Phase 4recruiting202535
Study to Demonstrate Pharmacokinetic and Pharmacodynamic Similarity Between NKF-INS(L), US-Humalog®, and EU-Humalog®Phase 1completed202554
Suppression of Endogenous Glucose Production by Injectable HDV-Insulin Lispro: A Dose Response Study in Human Subjects With Type 1 DiabetesPhase 1not yet recruiting202518
A Study of LY3938577 in Healthy Participants and Participants With Type 1 Diabetes Mellitus (T1DM)Phase 1completed2024121
Effects of Antipsychotics on Brain Insulin Action in Femalesactive not recruiting202415
A Study of LY900014 in Adult Participants With Type 2 Diabetes Mellitus in IndiaPhase 4completed2024153
Perioperative Glucose Monitoring and Treatment to Reduce Risk of Surgical Site Infections and Complicationsunknown2024266
Strict Versus Permissive Thresholds for Initiation of Pharmacotherapy in Gestational Diabetes (START 2)recruiting2024430
Strict Versus Permissive Thresholds for Initiation of Pharmacotherapy in Gestational Diabetesrecruiting2024430
Mealtime or Post-meal Dosing of URLi in Medtronic [amount hidden] Hybrid Closed Loop SystemPhase 4unknown202450
A Trial of Three- and Seven-days Insulin Infusions Setrecruiting202480
Does Abnormal Insulin Action in the Brain Underlie Cognitive and Metabolic Dysfunction in Schizophreniaactive not recruiting202320
Phase 2b Trial Comparing HDV-Insulin Lispro to Insulin Lispro in Adults With Type 1 Diabetes Receiving Insulin DegludecPhase 2completed2023227
A Study of LY8888AX in Participants Using a Connected Insulin Management Platformcompleted202336
A Fully Automated Lyumjev and Pramlintide Delivery System for Adults With Type 1 DiabetesPhase 2/Phase 3unknown202330
A Trial to Compare Automated Lyumjev Delivery With Carbohydrate Counting, Qualitative Meal-size Estimation, and Meal Detection in Type 1 DiabetesPhase 2unknown202312
Automated Fully Closed-Loop Insulin Delivery in Type 1 Diabetes With Ultra-Rapid Lispro (ACOLYTE Study)unknown202326
Glycemic Control After Antenatal Corticosteroids in Women With Pregestational and Gestational DiabetesPhase 2active not recruiting2022120
Ultrarapid Insulin Administered by a Bihormonal Closed Loop System in Patients With Type 1 Diabetescompleted202212
Efficacy and Safety of THDB0206 Compared to Insulin Lispro Injection in Participants With Type 2 DiabetesPhase 3completed20221040
Efficacy and Safety of THDB0206 Compared to Insulin Lispro Injection in Participants With Type 1 DiabetesPhase 3completed2022550
A Study of Insulin Efsitora Alfa (LY3209590) as a Weekly Basal Insulin Compared to Insulin Glargine in Adult Participants With Type 2 Diabetes on Multiple Daily InjectionsPhase 3completed2022730
A Study of LY900014 (Lyumjev) Versus Insulin Lispro (Humalog) in Participants With Type 1 DiabetesPhase 1completed202225
Efficacy and Safety of Dapagliflozin for the Hospital Management of Patients With Type 2 DiabetesPhase 4completed2022250
A Trial Investigating the Pharmacodynamics of BC Combo THDB0207 Compared With Humalog® Mix25 and Simultaneous Injections of Humalog® and Lantus® in Healthy Chinese VolunteersPhase 1completed202227
SITAgliptin Plus GLARgine to Glycemic Control in the Hospital Setting (SITAGLAR-H)Phase 4completed202276
A Trial Comparing the Pharmacodynamics and Pharmacokinetics of BC Combo THDB0207 and Lantus® and Humalog® in Subjects With Type 1 DiabetesPhase 1completed202230
A Trial Investigating the Dose Linearity and Safety of BC Combo THDB0207 in Subjects With Type 2 DiabetesPhase 1completed202240
Closing the Loop in Adults With Type 1 Diabetes Under Free Living Conditions (AP@Home04_Phase 4)completed202228
Is Brain Insulin Resistance a Feature of the Biology of Depression in Adolescentscompleted202124
Afrezza® INHALE-1 Study in PediatricsPhase 3completed2021319
Dynamics of Insulin Absorption in Subclinical Lipohypertrophy Using the Euglycemic Clamp Techniquewithdrawn2021
A Trial to Evaluate the Pharmacokinetics and Pharmacodynamics of THDB0206 Injection in Healthy Chinese SubjectsPhase 1completed202139
A Study of Infusion Site Pain After Infusion of Excipients in Participants With Type 1 Diabetes MellitusPhase 1completed202140

Peer-reviewed studies (420)

PaperAuthorsJournalYearType
Glucose-lowering in type 2 diabetes may be mediated by improved proinsulin processing without better β-cell compensationRetnakaran R et al.American journal of physiology. Endocrinology and metabolism2026Randomized Controlled Trial
Ultra-Rapid Lispro Has an Improved Pharmacokinetic Profile for Exercise Compared With Lispro, Resulting in Less Exercise-Associated Hypoglycemia in Adults With Type 1 Diabetes on Open-Loop Continuous Subcutaneous Insulin InfusionLeohr JK et al.Diabetes care2026Randomized Controlled Trial
Impact of Ultra-Rapid Insulin on Boost and Ease-Off in the Cambridge Hybrid Closed-Loop System for Individuals With Type 1 DiabetesRoyston C et al.Journal of diabetes science and technology2026Randomized Controlled Trial
Fully closed-loop control with ultra-rapid versus standard insulin lispro: A randomised crossover study simulating missed meal bolusesThabit H et al.Diabetic medicine : a journal of the British Diabetic Association2025Randomized Controlled Trial
Once-weekly insulin efsitora alfa versus once-daily insulin glargine U100 in adults with type 2 diabetes treated with basal and prandial insulin (QWINT-4): a phase 3, randomised, non-inferiority trialBlevins T et al.Lancet (London, England)2025Randomized Controlled Trial
Efficacy and hypoglycaemia outcomes with once-weekly insulin icodec versus once-daily basal insulin in individuals with type 2 diabetes by kidney function: A post hoc participant-level analysis of the ONWARDS 1-5 trialsRossing P et al.Diabetes, obesity & metabolism2025Randomized Controlled Trial
Pharmacokinetic and Pharmacodynamic Equivalence of Biosimilar and Reference Ultra-Rapid Lispro: A Comparative Clamp Study in Healthy VolunteersNoskov S et al.Clinical pharmacology in drug development2025Randomized Controlled Trial
Investigation of Severe Hypoglycemia Risk Among Patients with Diabetes Treated with Ultra-Rapid Lispro in JapanMizuno S et al.Advances in therapy2025Observational Study
Once-weekly insulin efsitora alfa versus once-daily insulin degludec in adults with type 1 diabetes (QWINT-5): a phase 3 randomised non-inferiority trialBergenstal RM et al.Lancet (London, England)2024Randomized Controlled Trial
ADO09, a co-formulation of pramlintide and insulin A[amount hidden], lowers body weight versus insulin lispro in type 1 diabetesAndersen G et al.Diabetes, obesity & metabolism2024Randomized Controlled Trial
Ultra rapid lispro improves postprandial glucose control versus lispro in combination with basal insulin: a study based on CGM in type 2 diabetes in ChinaYuan L et al.Frontiers in endocrinology2024Randomized Controlled Trial
Multicenter Evaluation of Ultra-Rapid Lispro Insulin with Control-IQ Technology in Adults, Adolescents, and Children with Type 1 DiabetesLevy CJ et al.Diabetes technology & therapeutics2024Clinical Trial
Postprandial Glucose Excursions with Ultra-Rapid Insulin Analogs in Hybrid Closed-Loop Therapy for Adults with Type 1 DiabetesHaliloglu B et al.Diabetes technology & therapeutics2024Randomized Controlled Trial
Ultra-rapid lispro improved postprandial glucose control compared to insulin lispro in predominantly Chinese patients with type 1 diabetes: A prospective, randomized, double-blind phase 3 studyMa J et al.Diabetes, obesity & metabolism2024Randomized Controlled Trial
Ultra rapid lispro (Lyumjev®) shortens time to recovery from hyperglycaemia compared to Humalog® in individuals with type 1 diabetes on continuous subcutaneous insulin infusionLeohr J et al.Diabetes, obesity & metabolism2024Randomized Controlled Trial
An Investigation Into Local Infusion Site Pain After Infusion of Ultra Rapid Lispro Excipients Across Sites and DepthsIgnaut D et al.Journal of diabetes science and technology2024Randomized Controlled Trial
Splitting Mealtime Insulin Doses for Mixed Fat and Protein Meals in Children and Adolescents with Type 1 Diabetes Using Multiple Daily Injection Regimen: A Randomized Cross-Over TrialHegab AM et al.Pediatric diabetes2023Randomized Controlled Trial
CamAPS FX Hybrid Closed-Loop with Ultra-Rapid Lispro Compared with Standard Lispro in Adults with Type 1 Diabetes: A Double-Blind, Randomized, Crossover StudyNwokolo M et al.Diabetes technology & therapeutics2023Randomized Controlled Trial
Tirzepatide vs Insulin Lispro Added to Basal Insulin in Type 2 Diabetes: The SURPASS-6 Randomized Clinical TrialRosenstock J et al.JAMA2023Randomized Controlled Trial
Pharmacokinetic and pharmacodynamic bioequivalence of Gan & Lee insulin analogues aspart (rapilin®), lispro (prandilin®) and glargine (basalin®) with EU- und US-sourced reference insulinsChen W et al.Diabetes, obesity & metabolism2023Randomized Controlled Trial
[Efficacy and safety of ultra rapid lispro in the treatment of type 2 diabetes mellitus: a randomized controlled clinical trial]Chen S et al.Zhonghua nei ke za zhi2023Randomized Controlled Trial
Fully Closed-Loop Glucose Control Compared With Insulin Pump Therapy With Continuous Glucose Monitoring in Adults With Type 1 Diabetes and Suboptimal Glycemic Control: A Single-Center, Randomized, Crossover StudyBoughton CK et al.Diabetes care2023Randomized Controlled Trial
Ultra rapid lispro showed greater reduction in postprandial glucose versus Humalog in children, adolescents and adults with type 1 diabetes mellitusAronson R et al.Diabetes, obesity & metabolism2023Randomized Controlled Trial
The vascular function effects of adding exenatide or meal insulin to basal insulin therapy in early type 2 diabetesRetnakaran R et al.Cardiovascular diabetology2023Randomized Controlled Trial
Evaluation of Insulin Lispro Pharmacokinetics and Pharmacodynamics Over 10 Days of Continuous Insulin Infusion in People With Type 1 DiabetesGarhyan P et al.Journal of diabetes science and technology2023Randomized Controlled Trial
Efficacy and safety of ultra-rapid lispro versus lispro in children and adolescents with type 1 diabetes: The PRONTO-Peds trialWadwa RP et al.Diabetes, obesity & metabolism2023Randomized Controlled Trial
Ultra rapid lispro improves postprandial glucose control versus lispro in combination with insulin glargine/degludec in adults with type 2 diabetes: a prospective, randomized, double-blind, phase 3 trialZhou J et al.Science bulletin2022Randomized Controlled Trial
The metabolic effects of adding exenatide to basal insulin therapy when targeting remission in early type 2 diabetes in a randomized clinical trialRetnakaran R et al.Nature communications2022Randomized Controlled Trial
Positive Impact of the Bionic Pancreas on Diabetes Control in Youth 6-17 Years Old with Type 1 Diabetes: A Multicenter Randomized TrialMesser LH et al.Diabetes technology & therapeutics2022Randomized Controlled Trial
A Multicenter Randomized Trial Evaluating the Insulin-Only Configuration of the Bionic Pancreas in Adults with Type 1 DiabetesKruger D et al.Diabetes technology & therapeutics2022Randomized Controlled Trial

More cited research

Conditions researched

Related compounds

FAQ

What is Insulin Lispro?

A rapid-acting mealtime insulin analog; brands include Humalog, Admelog and Lyumjev.

How many registered human trials study Insulin Lispro?

The PeptideWhiz trial index lists 314 registered trials for Insulin Lispro, the most recent from 2026.

How much published research exists on Insulin Lispro?

The PeptideWhiz paper index links 420 PubMed papers to Insulin Lispro; by study type, 464 human and 0 animal studies.

Which conditions is Insulin Lispro researched for?

Atherosclerosis, cardiovascular disease & high blood pressure, Chronic and systemic inflammation, Cognition, focus & brain performance, Concussion, traumatic brain injury & stroke recovery, Delayed gastric emptying on GLP-1 medicines, Dementia, Alzheimer's & cognitive decline, Fat loss, obesity & body recomposition, Fatty liver & elevated liver enzymes, Heart repair: after heart attack, heart failure & enlarged heart, Insulin resistance, prediabetes & type 2 diabetes, Kidney protection (CKD, diabetic kidney, lupus kidney), Low blood pressure and orthostatic hypotension, Lung health, asthma & COPD, Muscle gain, sarcopenia & building muscle after 40, Neuropathy and CRPS, Post-surgical inflammation and surgery recovery, Pregnancy and breastfeeding: safety notes.

Research and education only. Not medical advice. No dosing guidance. Data: ClinicalTrials.gov registry and PubMed via the PeptideWhiz index (204,289 studies).

Reported dosing ranges from research